The manufacturing company is vertically integrated and manufactures these and other products from active pharmaceutical ingredient (API) to finished dosage forms. The manufacturer has USFDA and EU approved manufacturing facilities.
One of these molecules ranks among the top 3 molecules in Canadian generics market in 2015, with the market size of approximately $150 million (source:IMS Health); the other product will become off patent in 2017.
"We are very excited to have signed this agreement and to be submitting our very own ANDS in the near future. ANDS filings give VANC the opportunity to move up the value chain in the generic market space." said Arun Nayyar, CEO of VANC.
"Once approved by Health Canada these products will offer enormous strength to our generic product portfolio. VANC will continue to source more molecules via the ANDS route to further expand our generic portfolio with higher margin products."